{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05417971",
            "orgStudyIdInfo": {
                "id": "NSH 1347"
            },
            "organization": {
                "fullName": "Northside Hospital, Inc.",
                "class": "OTHER"
            },
            "briefTitle": "Reduced Intensity Fludarabine and TBI Prior to Haplo-Identical Transplantation",
            "officialTitle": "A Phase II Trial of Reduced Intensity Fludarabine and Total Body Irradiation-Based Conditioning Prior to Haplo-Identical Transplantation for Patients With Hematologic Malignancies",
            "therapeuticArea": [
                "Other"
            ],
            "study": "reduced-intensity-fludarabine-and-tbi-prior-to-haplo-identical-transplantation"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-08-29",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-07-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-05-31",
            "studyFirstSubmitQcDate": "2022-06-10",
            "studyFirstPostDateStruct": {
                "date": "2022-06-14",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-12",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-15",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Northside Hospital, Inc.",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This trial will evaluate the safety and efficacy of RIC HIDT transplant protocol following fludarabine and intermediate-dose TBI 800 cGy utilizing PBSC as the stem cell source."
        },
        "conditionsModule": {
            "conditions": [
                "Hematologic Malignancy"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "COHORT",
                "timePerspective": "PROSPECTIVE"
            },
            "enrollmentInfo": {
                "count": 20,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "interventions": [
                {
                    "type": "OTHER",
                    "name": "Fludarabine",
                    "description": "Reduced-intensity fludarabine with intermediate-dose TBI",
                    "otherNames": [
                        "Total Body Irradiation"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Compare the time to recovery of circulating neutrophils and platelets of all patients to determine incidence of graft rejection",
                    "timeFrame": "30 days after transplant"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Number of patients who are still alive as assessed by survival status at certain timepoints after transplant",
                    "timeFrame": "36 months after transplant"
                },
                {
                    "measure": "Number of patients with relapsed disease as assessed by labs, bone marrow biopsies and radiological scans at certain timepoints after transplant",
                    "timeFrame": "36 months after transplant"
                },
                {
                    "measure": "Number of patients with evidence of graft versus host disease as assessed by weekly progress notes after transplant",
                    "timeFrame": "36 months after transplant"
                },
                {
                    "measure": "Number of participants who died in the absence of relapse or progression as assessed by survival status at certain timepoints after transplant",
                    "timeFrame": "1 year after transplant"
                },
                {
                    "measure": "Number of participants with responses to treatment as assessed by labs, bone marrow biopsies and radiological scans at certain timepoints after transplant",
                    "timeFrame": "36 months after transplant"
                },
                {
                    "measure": "Number of participants with treatment-related adverse events as assessed by CTCAE v.5.0",
                    "timeFrame": "90 days after transplant"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Availability of 3/6 - 5/6 matched related donor with a negative HLA-cross match in the host vs. graft direction willing to donate peripheral blood stem cells\n* KPS \\>/= 70%\n* Hematologic malignancy requiring allogeneic transplantation, with a predicted high risk of relapse following non-myeloablative, low intensity conditioning.\n\nExclusion Criteria:\n\n* Poor cardiac function (LVEF \\<45%)\n* Poor pulmonary function (FEV, FVC, DLCO \\<60%)\n* Poor liver function (bilirubin \\>/= 2.5mg/dL; AST or ALT \\>3xULN)\n* Poor renal function (creatinine clearance \\<40mL/min)\n* HIV-positive; active HepB or HepC\n* Uncontrolled infection\n* Pregnant female or not able to practice adequate contraception\n* Debilitating medical or psychiatric illness which would preclude their giving informed consent",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "Male or female patients with any hematologic malignancy that requires an allogeneic transplant from a halpo-identical matched related donor",
            "samplingMethod": "PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Stacey Brown",
                    "role": "CONTACT",
                    "phone": "404-480-7965",
                    "email": "stacey.brown@northside.com"
                },
                {
                    "name": "Caitlin Guzowski",
                    "role": "CONTACT",
                    "phone": "404-851-8523",
                    "email": "caitlin.guzowski@northside.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Scott Solomon, MD",
                    "affiliation": "BMTGA",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Caitlin Guzowski",
                    "status": "RECRUITING",
                    "city": "Atlanta",
                    "state": "Georgia",
                    "zip": "30342",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Caitlin Guzowski, MBA, MHA",
                            "role": "CONTACT",
                            "phone": "404-851-8523",
                            "email": "caitlin.guzowski@northside.com"
                        },
                        {
                            "name": "H. Kent Holland, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Asad Bashey, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Lawrence E Morris, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Scott Solomon, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Melhem Solh, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Lizamarie Bachier-Rodriguez, MD",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.749,
                        "lon": -84.38798
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000019337",
                    "term": "Hematologic Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M21314",
                    "name": "Hematologic Neoplasms",
                    "asFound": "Hematologic Malignancies",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000024352",
                    "term": "Fludarabine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M283230",
                    "name": "Fludarabine",
                    "asFound": "Rate",
                    "relevance": "HIGH"
                },
                {
                    "id": "M225513",
                    "name": "Fludarabine phosphate",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}